Here is what participants achieved on average: Mounjaro (tirzepatide 15mg) SURMOUNT-1: Week 4: approximately 2 to 3% body weight loss Week 12: approximately 7 to 8% Week 24: approximately 13 to 15% Week 52: approximately 18 to 20% Week 72 (end of trial): average 20.9% Wegovy (semaglutide 2.4mg) STEP 1: Week 4: approximately 1 to 2% body weight loss Week 12: approximately 5 to 6% Week 24: approximately 9 to 10% Week 52: approximately 12 to 14% Week 68 (end of trial): average 14.9% These are averages
The results showed that Tanzeum bound with slightly faster association and dissociation rates than GLP-1 WT, resulting in a 1.5-fold difference in binding affinity to the receptor (Tanzeum: 76.1 nM
La estabilidad gstrica intrnseca del pptido y su secuencia rica en prolina lo hacen ms resistente a la degradacin enzimtica que la mayora de los pptidos, pero sigue siendo necesario refrigerar
Exclusion criteria included the Concept ID for diagnoses of Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Elevated HbA1C levels (6.5), and conditions that would increase fracture risk, including diagnoses for: Osteoporosis, Rheumatoid Arthritis, Chronic Kidney Disease, and Long-term Corticosteroid Use
)
